| Ident. | Authors (with country if any) | Title |
|---|
| 000599 |
Penelope J. Hallett [États-Unis] ; J. M. Brotchie [Canada] | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia |
| 000793 |
Bianca Marchetti [Italie] ; Pier Andrea Serra [Italie] ; Cataldo Tirolo [Italie] ; Francesca L'Episcopo [Italie] ; Salvo Caniglia [Italie] ; Florinda Gennuso [Italie] ; Nuccio Testa [Italie] ; Egidio Miele [Italie] ; Speranza Desole [Italie] ; Nicholas Barden [Canada] ; Maria Concetta Morale [Italie] | Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism : pivotal role for glia-neuron interactions |
| 000988 |
J. Q. Lu [Canada] ; A. J. Stoessl [Canada] | Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats |
| 000B94 |
C. S. Lee [Canada] ; M. A. Cenci [Suède] ; M. Schulzer [Canada] ; A. Björklund [Suède] | Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease |
| 000C23 |
M. C. Evans [États-Unis] ; A. Pradhan [Canada] ; S. Venkatraman [États-Unis] ; W. H. Ojala [États-Unis] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring α, α-disubstituted amino acids |
| 000C56 |
T. Inoue [Canada, Japon] ; J. Tsui [Canada] ; N. Wong [Canada] ; SHIN YI WONG [Canada] ; F. Suzuki [Japon] ; YIN NAM KWOK [Canada] | Expression of glial cell line-derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment |
| 000C64 |
E. M. Khalil [États-Unis] ; W. H. Ojala [États-Unis] ; A. Pradhan [Canada] ; V. D. Nair [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide |
| 000D78 |
N. A. Tatton [Canada] ; S. J. Kish [Canada] | In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and Acridine Orange Staining |
| 000D93 |
P. W. Baures [États-Unis] ; W. H. Ojala [États-Unis] ; W. J. Costain [Canada] ; M. C. Ott [Canada] ; A. Pradhan [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide |
| 000E26 |
E. I. Miklyaeva [Canada] ; I. Q. Whishaw [Canada] | HemiParkinson analogue rats display active support in good limbs versus passive support in bad limbs on a skilled reaching task of variable height |
| 000F10 |
P. J. Blanchet [Canada] ; R. Boucher [Canada] ; P. J. Bedard | Excitotoxic lateral pallidotomy does not relieve L-DOPA-induced dyskinesia in MPTP parkinsonian monkeys |
| 000F36 |
M. Takada [Canada] ; T. Sugimoto ; T. Hattori [Canada] | MPTP neurotoxicity to cerebellar Purkinje cells in mice |
| 000F44 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 000F46 |
B. D. Pate [Canada] ; T. Kawamata ; T. Yamada ; E. G. Mcgeer [Canada] ; K. A. Hewitt [Canada] ; B. J. Snow [Canada] ; T. J. Ruth [Canada] ; D. B. Calne [Canada] | Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices |
| 000F50 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada] | Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors |
| 000F79 |
A. Tabatabaei [Canada] ; T. L. Perry ; S. Hansen ; C. Krieger | Partial protective effect of MK-4801 on MPTP-induced reduction of striatal dopamine in mice |
| 000F89 |
B. Gomez-Mancilla [Canada] ; J.-F. Latulippe ; R. Boucher ; P. J. Bedard | Effect of ethosuximide on rest tremor in the MPTP monkey model |
| 000F91 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys |
| 000F92 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
| 000F97 |
M. L. Paul [Canada] ; A. M. Graybiel ; J.-C. David ; H. A. Robertson [Canada] | D1-like and D2-like dopamine receptors synergistically actitave rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease |
| 001013 |
R. Rivest ; S. St-Pierre ; F. B. Jolicoeur | Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat |
| 001015 |
W. G. Tatton [Canada] ; C. E. Greenwood | Rescue of dying neurons : a new action for deprenyl in MPTP parkinsonism |
| 001026 |
F. B. Jolicoeur [Canada] ; R. Rivest ; A. Drumheller | Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat |
| 001029 |
M. Filion ; L. Tremblay ; P. J. Bedard | Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism |
| 001030 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism |
| 001033 |
D. B. Calne ; M. J. Zigmond | Compensatory mechanisms in degenerative neurologic diseases : insights from Parkinsonism |
| 001037 |
F. B. Jolicoeur ; R. Rivest ; S. St.-Pierre ; A. Drumheller | Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats |
| 001040 |
M. Filion ; L. Tremblay | Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism |
| 001054 |
D. Pare ; R. Curro'Dossi ; M. Steriade | Neuronal basis of the Parkinsonian resting tremor : a hypothesis and its implications for treatment |
| 001058 |
M. Guttman ; H. C. Fibiger ; A. Jakubovic ; D. B. Calne | Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism |
| 001063 |
C. Rouillard ; P. J. Bedard ; T. Di Paolo | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
| 001064 |
C. Gagnon ; P. J. Bedard ; T. Di Paolo | Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists |
| 001079 |
T. L. Perry ; C. Bergeron ; A. J. Biro ; S. Hansen | β-N-methylamino-L-alanine: chronic oral administration is not neurotoxic to mice |
| 001081 |
VOON WEE YONG ; M. Guttman ; S. U. Kim ; D. B. Calne ; I. Turnbull ; K. Watabe ; R. W. W. Tomlinson | Transplantation of human sympathetic neurons and adrenal chromaffin cells into parkinsonian monkeys: no reversal of clinical symptoms |
| 001093 |
G. S. Robertson ; D. G. Herrera ; M. Dragunow ; H. A. Robertson | L-DOPA activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra |
| 001096 |
P. J. Bedard ; R. Boucher | Effect of D1 receptor stimulation in normal and MPTP monkeys |
| 001108 |
T. L. Perry ; K. Jones ; S. Hansen | Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice |
| 001112 |
M. Pisa | Regional specialization of motor functions in the rat striatum: implications for the treatment of parkinsonism |
| 001126 |
P. Falardeau ; S. Bouchard ; P. J. Bedard ; R. Boucher ; T. Di Paolo | Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2dopamine agonists in MPTP monkeys |
| 001129 |
M. Filion ; L. Tremblay ; P. J. Bedard | Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys |
| 001130 |
E. C. Wolters ; J. C. Kebabian ; M. Guttman ; E. Mak ; B. D. Pate ; D. B. Calne | A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys |
| 001132 |
J. H. Thakar ; M. N. Hassan ; J. D. Grimes | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), its metabolite cyperquat (MPP+) and energy transduction in mitochondria from rat striatum and liver |
| 001171 |
T. Di Paolo ; P. Bedard ; M. Daigle ; R. Boucher | Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys |
| 001173 |
H. Kamo ; S. U. Kim ; P. L. Mcgeer ; D. H. Shin | Functional recovery in a rat model of Parkinson's disease following transplantation of cultured human sympathetic neurons |
| 001184 |
P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |
